New data show HOOKIPA's arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigens
Preclinical data on combination with co-stimulatory 4-1BB agonists or adoptive T cell transfer showed potent T cell responses and significant tumor controlPreclinical data also expand evidence on... | April 13, 2022